Quick Answer
Protagenic Therapeutics, Inc.new reported Cash and Equivalents of $671.1 thousand for fiscal year 2020.
Protagenic Therapeutics, Inc.new Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2020 | $671.1K | -16.0% |
| 2019 | $798.6K | +120.3% |
| 2018 | $362.5K | -9.3% |
| 2017 | $399.7K | -87.1% |
| 2016 | $3.10M | +92643.0% |
| 2015 | $3.3K | -94.6% |
| 2015 | $62.0K | +172.7% |
| 2014 | $22.7K | -77.5% |
| 2014 | $101.0K | -85.9% |
| 2013 | $717.0K | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| March 31, 2021 | $191.7K | -74.6% | -71.4% |
| December 31, 2020 | $671.1K | -16.0% | -32.1% |
| September 30, 2020 | $988.6K | +256.4% | -16.3% |
| June 30, 2020 | $1.18M | +247.9% | +56.7% |
| March 31, 2020 | $754.0K | — | -5.6% |
| December 31, 2019 | $798.6K | +120.3% | +187.9% |
| September 30, 2019 | $277.4K | -35.8% | -18.3% |
| June 30, 2019 | $339.5K | +43.9% | -6.3% |
- Protagenic Therapeutics, Inc.new showed a decrease of -16.0% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2013–2020 period, Protagenic Therapeutics, Inc.new’s cash and equivalents has declined by 6.4% (from $717.0 thousand to $671.1 thousand).
- The most recent figure is from Protagenic Therapeutics, Inc.new’s fiscal year 2020 report (Form 10-K), filed with the SEC on March 25, 2021.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: